关于
  • English
  • About
    • About Sirona
    • Management
    • Board of Directors
    • Strategic Advisory Board
    • Our Partners
  • TFChem
    • About TFChem
    • Management
    • Team
    • TFChem Laboratory Capabilities
  • Programs
    • Proprietary Platform Technology
    • Pipeline
    • Diabetes – SGLT2 Inhibitor
    • Skincare – Dark Spot Correction
    • Skincare – Anti-Aging / Anti-Wrinkle
    • Antiviral
  • News
    • Sirona News
    • Events
  • Investors
    • Financial Information
    • Financial Reports
    • Investor & Media Kit
    • Newsletter
  • Contact
  • Careers

News

March 9th, 2022

Sirona Biochem Subsidiary, TFChem, Awarded Financing in Partnership with French Government

January 18th, 2022

Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support

January 12th, 2022

Sirona Biochem Sponsors Fluorine Chemistry Symposium, Normandy, France

January 4th, 2022

Sirona Biochem CEO Quarterly Update

December 20th, 2021

Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 52
  • Next Page »

Archives

  • About
  • TFChem
  • Programs
  • News
  • Investors
  • Contact

© 2022 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

© 2022 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

General inquires: 604.641.4466
Investor inquiries (Momentum PR): 450.332.6939
info@sironabiochem.com

Enter your info below to subscribe to our newsletter: